X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (303) 303
life sciences & biomedicine (274) 274
humans (210) 210
melanoma (194) 194
oncology (183) 183
melanoma - drug therapy (119) 119
male (117) 117
female (113) 113
middle aged (102) 102
adult (91) 91
melanoma - genetics (91) 91
aged (88) 88
mutation (87) 87
metastasis (85) 85
proto-oncogene proteins b-raf - genetics (84) 84
melanoma - pathology (74) 74
immunotherapy (72) 72
cancer (63) 63
proto-oncogene proteins b-raf - antagonists & inhibitors (63) 63
metastases (60) 60
patients (59) 59
skin neoplasms - drug therapy (55) 55
care and treatment (53) 53
aged, 80 and over (52) 52
treatment outcome (50) 50
cell biology (47) 47
clinical trials (47) 47
skin neoplasms - pathology (42) 42
melanoma - mortality (41) 41
young adult (40) 40
tumors (39) 39
skin neoplasms - genetics (36) 36
abridged index medicus (35) 35
survival (35) 35
analysis (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
imidazoles - administration & dosage (34) 34
oximes - administration & dosage (34) 34
antineoplastic agents - therapeutic use (33) 33
melanoma - secondary (31) 31
adolescent (30) 30
prognosis (30) 30
disease-free survival (29) 29
protein kinase inhibitors - therapeutic use (29) 29
immune checkpoint (28) 28
drug therapy (27) 27
melanoma - metabolism (27) 27
risk factors (27) 27
ipilimumab (26) 26
braf (25) 25
general & internal medicine (25) 25
medicine, general & internal (25) 25
skin neoplasms - mortality (25) 25
hematology, oncology and palliative medicine (24) 24
neoplasm metastasis (24) 24
pathology (24) 24
pyridones - administration & dosage (24) 24
pyrimidinones - administration & dosage (24) 24
cell line, tumor (23) 23
dermatology (23) 23
antibodies, monoclonal - therapeutic use (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
biochemistry & molecular biology (22) 22
imidazoles - adverse effects (22) 22
medical research (22) 22
oximes - adverse effects (22) 22
pd-1 protein (22) 22
melanoma - immunology (21) 21
neoplasm staging (21) 21
research (21) 21
immunohistochemistry (20) 20
mek inhibitors (20) 20
multidisciplinary sciences (20) 20
neoplasms (20) 20
patient outcomes (20) 20
science & technology - other topics (20) 20
therapy (20) 20
610 medicine & health (19) 19
disease progression (19) 19
kaplan-meier estimate (19) 19
melanoma - therapy (19) 19
proto-oncogene proteins b-raf - metabolism (19) 19
toxicity (19) 19
animals (18) 18
dabrafenib (18) 18
diagnosis (18) 18
gene expression (18) 18
imidazoles - therapeutic use (18) 18
lymphocytes t (18) 18
nivolumab (18) 18
oximes - therapeutic use (18) 18
biopsy (17) 17
medical prognosis (17) 17
protein kinase inhibitors - administration & dosage (17) 17
pyridones - adverse effects (17) 17
pyrimidinones - adverse effects (17) 17
studies (17) 17
survival analysis (17) 17
biomarkers (16) 16
cancer therapies (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 10/2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
Journal Article
The lancet oncology, ISSN 1470-2045, 09/2019, Volume 20, Issue 9, pp. 1239 - 1251
SummaryBackgroundPembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a... 
Hematology, Oncology, and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Ipilimumab | Analysis | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 08/2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2014, Volume 371, Issue 20, pp. 1877 - 1888
Journal Article